25 May 2013
Keywords: neurocrine, indiplon, profile, backed, ph, iii, biosciences
Article | 26 May 2003
Neurocrine Biosciences of the USA has reported promising Phase III data on its novel hypnotic drug indiplon which suggest that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 May 2003
2 June 2003
24 May 2013
© 2013 thepharmaletter.com